Cardiology 2010-01-01

Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure--association with signs and symptoms, hospitalization duration, and 60-day outcomes.

Gad Cotter, Marco Metra, Beth Davison Weatherley, Howard C Dittrich, Barry M Massie, Piotr Ponikowski, Daniel M Bloomfield, Christopher M O'Connor

Index: Cardiology 115(1) , 29-36, (2010)

Full Text: HTML

Abstract

To evaluate physician-determined worsening heart failure (PD-WHF) in patients admitted with acute heart failure (AHF).The PROTECT pilot study evaluated rolofylline, an adenosine A(1) receptor antagonist, versus placebo in patients with AHF and renal impairment. Signs and symptoms of heart failure (HF) and diuretic administration were prospectively recorded daily for 7 days and patients were followed for 60 days. Patients were categorized into three groups: (A) PD-WHF, based on worsening symptoms and signs of HF and need for additional intravenous (IV) or mechanical therapy (n = 29); (B) increased IV diuretic therapy without PD-WHF (n = 61), and (C) neither PD-WHF nor increase in IV diuretic dose (n = 211).Patients in group A had slower resolution of dyspnea, longer mean (+/-SD) length of hospitalization (13.8 +/- 6.8 vs. 10.5 +/- 8.5 and 9.3 +/- 5.9 days in groups B and C, respectively; p < 0.05 for both), and higher 60-day death and cardiovascular or renal readmission rates [49.7 (95% confidence interval: 33.1-69.1) vs. 37.3 (26.4-50.9) vs. 19.5% (14.7-25.6) in groups B and C, respectively]. PD-WHF was a strong independent predictor of length of stay and 60-day death and cardiovascular or renal readmission.PD-WHF may be an indicator of short-term risk and treatment efficacy in AHF.(c) 2009 S. Karger AG, Basel.


Related Compounds

Related Articles:

The effects of multiple doses of rolofylline on the single-dose pharmacokinetics of midazolam in healthy subjects.

2010-01-01

[Am. J. Ther. 17(1) , 53-60, (2010)]

The disconnect between phase II and phase III trials of drugs for heart failure.

2013-02-01

[Nat. Rev. Cardiol. 10(2) , 85-97, (2013)]

Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function.

2010-01-01

[J. Card. Fail. 16(1) , 25-35, (2010)]

Adenosine A2 receptor activation attenuates afferent arteriolar autoregulation during adenosine receptor saturation in rats.

2007-10-01

[Hypertension 50(4) , 744-9, (2007)]

Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function.

2010-11-01

[Eur. J. Heart Fail. 12(11) , 1238-46, (2010)]

More Articles...